Last update 21 Nov 2024

Mesenchymal stem cell therapy (Longeveron)

Overview

Basic Info

Drug Type
Mesenchymal stem cell therapy
Synonyms
Allogeneic Human Mesenchymal Stem Cells, LOMECELB, Longeveron human mesenchymal stem cells
+ [1]
Target
Mechanism
MMP14 inhibitors(Matrix metalloproteinase 14 inhibitors), Cell replacements
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationRare Pediatric Disease (US), Fast Track (US), Orphan Drug (US), Regenerative Medicine Advanced Therapy (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alzheimer DiseasePhase 2
US
28 Dec 2021
Hypoplastic Left Heart SyndromePhase 2
US
25 Jun 2021
COVID-19Phase 1
US
24 Jul 2020
Influenza, HumanPhase 1
US
24 Jul 2020
Respiratory Distress Syndrome, AcutePhase 1
US
24 Jul 2020
Cognition DisordersDiscovery
BS
25 Apr 2021
OsteoarthritisDiscovery
BS
25 Apr 2021
Metabolic SyndromeDiscovery
US
08 Sep 2020
Frailty SyndromeDiscovery
US
06 Jul 2017
Cardiomyopathy, DilatedDiscovery
US
23 Jun 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
10
(cpxbsyjyva) = wxxlqxzswy ivpgivnevw (ikdqxrbguu )
Positive
27 Oct 2024
historical Comparator (SVR Trial)
(cpxbsyjyva) = azuzwwndkg ivpgivnevw (ikdqxrbguu )
Phase 2
48
(ihmspofzxo) = The established safety profile of Lomecel-B™ for single and multiple dosing regimens was demonstrated in study data that showed no incidence of hypersensitivity, infusion-related reactions, and no cases of amyloid-related imaging abnormalities (ARIA). opgmnnnaqp (gkftwgftll )
Positive
28 Jul 2024
Placebo
Phase 2
49
(qeobaqgnpj) = Lomecel-B™ (100M x 4 doses) demonstrated a higher level of improvement in quality of life observed by caregiver and measured by Alzheimer’s Disease Related Quality of Life scale (ADRQOL). usipvytilv (zwbiekuhps )
Positive
20 Dec 2023
(25M x 1 dose)
Phase 1
33
tumuzogwuo(bjtwromanl) = jqbqgminkk vvoygevqlj (kxeogdxhjl )
Positive
31 Dec 2021
Phase 1/2
37
(Autologous hMSCs)
(figdoevwlt) = amzhlekdyf ohysxtblld (saqcubkrvs, gwnzswzeln - zgrxqyunii)
-
15 Feb 2018
(Allogeneic hMSCs)
(figdoevwlt) = qvhhkjwxak ohysxtblld (saqcubkrvs, ewfpnrytrv - qwyndhopzc)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free